Johnson & Johnson  

(Public, NYSE:JNJ)   Watch this stock  
Find more results for E. Johnson
107.21
+0.51 (0.48%)
Nov 26 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 106.60 - 107.25
52 week 86.09 - 109.49
Open 106.77
Vol / Avg. 5.50M/8.22M
Mkt cap 300.09B
P/E 17.75
Div/yield 0.70/2.61
EPS 6.04
Shares 2.80B
Beta 0.55
Inst. own 67%
Jan 19, 2015
Q4 2014 Johnson & Johnson Earnings Release (Estimated) - 12:01AM EST - Add to calendar
Oct 14, 2014
Q3 2014 Johnson & Johnson Earnings Release
Oct 14, 2014
Q3 2014 Johnson & Johnson Earnings Call - Webcast
Sep 10, 2014
Johnson & Johnson at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 25.72% 19.40%
Operating margin 36.88% 21.69%
EBITD margin - 33.30%
Return on average assets 14.25% 10.89%
Return on average equity 24.64% 19.92%
Employees 128,100 -
CDP Score - 98 A-

Address

ONE JOHNSON & JOHNSON PLZ
NEW BRUNSWICK, NJ 8933
United States - Map
+1-732-5242455 (Phone)
+1-732-2140332 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Johnson & Johnson is a holding company engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products in virtually all countries throughout the world. The Company also provides therapeutics for viral infections with the compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus (RSV). It also owns two early-stage compounds for hepatitis C (HCV). The Company´┐Żs primary focus has been on products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Company's subsidiaries operate 146 manufacturing facilities occupying approximately 21.6 million square feet of floor space.

Officers and directors

Alex Gorsky Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Dominic J. Caruso Chief Financial Officer, Vice President - Finance
Age: 56
Bio & Compensation  - Reuters
Sandra E. Peterson Group Worldwide Chairman
Age: 55
Bio & Compensation  - Reuters
Paulus Stoffels Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group
Age: 52
Bio & Compensation  - Reuters
Michael H. Ullmann Vice President, General Counsel
Age: 55
Bio & Compensation  - Reuters
Peter M. Fasolo Ph.D. Vice President - Global Human Resources
Age: 51
Bio & Compensation  - Reuters
Ernesto Quinteros Chief Design Officer
Age: 51
Bio & Compensation  - Reuters
Anne M. Mulcahy Lead Independent Director
Age: 61
Bio & Compensation  - Reuters
D. Scott Davis Director
Age: 62
Bio & Compensation  - Reuters
Mary Sue Coleman Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters